<DOC>
	<DOCNO>NCT00309842</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy drug , fludarabine cyclophosphamide , total-body irradiation donor umbilical cord blood stem cell transplant help stop growth cancer cell prepare patient 's bone marrow stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil may stop happen . PURPOSE : This phase II trial study well give fludarabine cyclophosphamide together total-body irradiation work treat patient undergo umbilical cord blood transplant hematologic cancer .</brief_summary>
	<brief_title>Myeloablative Umbilical Cord Blood Transplantation Hematological Diseases</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 1-year survival patient undergo unrelated umbilical cord blood transplantation ( UCBT ) hematologic malignancy treat myeloablative preparative regimen comprise fludarabine , cyclophosphamide , fractionate total-body irradiation . Secondary - Determine incidence transplant-related mortality 6 month UCBT . - Evaluate pattern chimerism double UCBT . - Determine incidence neutrophil engraftment day 42 UCBT . - Determine incidence platelet engraftment 6 month UCBT . - Determine incidence grade II-IV grade III-IV acute graft-versus-host disease ( GVHD ) day 100 UCBT . - Determine incidence chronic GVHD 1 year UCBT . - Determine disease-free survival 1 2 year UCBT . - Determine incidence relapse 1 year UCBT . OUTLINE : This nonrandomized , open-label , multicenter study . - Preparative Regimen : Patients receive fludarabine IV 1 hour day -8 -6 cyclophosphamide IV day -7 -6 . Patients also undergo total-body irradiation twice daily day -4 -1 . - Umbilical Cord Blood Transplantation ( UCBT ) : Patients undergo 1 2 unit UCBT day 0 . Patients receive filgrastim ( G-CSF ) IV daily begin day 1 continue blood count recover . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive cyclosporine IV 2 hour 2 3 time daily begin day -3 continue day 100 follow taper day 180 . Patients also receive mycophenolate mofetil IV orally 2 3 time day begin day -3 continue day 30 7 day engraftment absence acute GVHD . After completion study treatment , patient follow periodically least 5 year . PROJECTED ACCRUAL : A total 150 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Acute myeloid leukemia ( AML ) : high risk CR1 ( evidence precede myelodysplastic syndrome [ MDS ] , high risk cytogenetics , ≥ 2 cycle obtain complete remission [ CR ] , erythroblastic megakaryocytic leukemia ; CR2+ . All patient must CR defined hematological recovery , AND &lt; 5 % blast light microscopy within bone marrow cellularity ≥15 % . Very high risk pediatric patient AML . Patients &lt; 21 year , however , eligible ( M2 marrow ) &lt; = 25 % blast marrow fail one cycle chemotherapy . This group patient analyze separately . Acute lymphocytic leukemia ( ALL ) : high risk CR1 [ ( 9 ; 22 ) , ( 1:19 ) , ( 4 ; 11 ) MLL rearrangement ] hypodiploidy , IKZF1 abnormality ) , DNA index &lt; 0.81 , &gt; 1 cycle obtain CR presence minimal residual disease ( MRD ) . Patients CR2+ eligible . All patient must CR defined hematological recovery , AND &lt; 5 % blast light microscopy within bone marrow cellularity ≥15 % . Very high risk pediatric patient ALL . patient &lt; 21 year also consider high risk CR1 M2 M3 marrow day 42 initiation induction M3 marrow end induction . They eligible achieved complete remission Chronic myelogenous leukemia ( CML ) exclude refractory blast crisis . To eligible first chronic phase ( CP1 ) patient must fail intolerant imatinib mesylate . Plasma Cell leukemia initial therapy , achieve least partial remission Advanced myelofibrosis Myelodysplasia ( MDS ) IPSS Int2 High risk ( i.e . RAEB , RAEBt ) refractory anemia severe pancytopenia high risk cytogenetics . Blasts must &lt; 10 % representative bone marrow aspirate morphology . Chronic lymphocytic leukemia/small lymphocytic lymphoma ( CLL/SLL ) , marginal zone Bcell lymphoma follicular lymphoma eligible disease progression/relapse within 12 achieve partial complete remission . Patients remission last &gt; 12 month , eligible least two prior therapy . Patients bulky disease ( nodal mass great 5 cm ) consider debulking chemotherapy transplant . Lymphoplasmacytic lymphoma , mantlecell lymphoma , prolymphocytic leukemia eligible initial therapy CR1+ PR1+ . Large cell NHL &gt; CR2/ &gt; PR2 . Patients CR2/PR2 initial short remission ( &lt; 6 month ) eligible . Lymphoblastic lymphoma , Burkitt 's lymphoma , highgrade NHL initial therapy stage III/IV CR1/PR1 progression stage I/II &lt; 1 year . Multiple myeloma beyond PR2 . Patients chromosome 13 abnormality , first response last less 6 month , β2 microglobulin &gt; 3 mg/L , may consider protocol initial therapy . Recipients must Karnofsky score ( adult ) ≥ 80 % Lansky score ≥ 50 % ( pediatrics ) , proper organ function . Exclusion Criteria Active infection time transplantation History human immunodeficiency virus ( HIV ) infection Pregnant breast feeding . Chemotherapy refractory large cell high grade NHL If &lt; = 18 year old , prior myeloablative transplant within last 6 month . If &gt; 18 year old prior myeloablative allotransplant autologous transplant Extensive prior therapy include &gt; 12 month alkylator therapy &gt; 6 month alkylator therapy extensive radiation . Patients receive Y90 ibritumomab ( Zevalin ) I131 tostumomab ( Bexxar ) , part salvage therapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent follicular lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>adult lymphoblastic lymphoma</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>Burkitt lymphoma</keyword>
	<keyword>childhood large cell lymphoma</keyword>
	<keyword>adult Burkitt lymphoma</keyword>
	<keyword>mantle cell lymphoma</keyword>
	<keyword>childhood lymphoblastic lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>